Acute Lymphocytic Leukemia Treatment

Acute lymphocytic leukemia (ALL) is a fast-growing cancer of the blood and bone marrow that arises from the lymphoid cell line, a group of white blood cells that play a key role in the body’s immune response. ALL specifically affects lymphoblasts, immature cells that normally develop into lymphocytes that recognize and fight viruses, bacteria and other harmful invaders. In ALL, lymphoblasts multiply uncontrollably and fail to mature into functional lymphocytes. As a result, the abnormal cells accumulate in the bone marrow and bloodstream, crowding out healthy blood cells.

ALL is the most common type of childhood leukemia, but it affects people of all ages. Symptoms can include easy bleeding, unexplained bruising, fatigue, frequent infections, bone pain and swollen lymph nodes. While the exact cause is often unknown, scientists believe certain genetic mutations and environmental exposures may play a role in its development. Typically, the diagnostic process includes blood work, bone marrow biopsy and genetic testing.

Treatment for acute lymphocytic leukemia can vary based on the patient’s age and risk profile. Options may include:

Chemotherapy for acute lymphocytic leukemia

The foundation of ALL treatment is chemotherapy, which uses powerful medications to destroy rapidly dividing cells throughout the body, including leukemic cells in the blood and bone marrow. Chemotherapy may be administered intravenously, orally or directly into the spinal fluid to reach leukemic cells in the central nervous system (CNS). Most patients receive a combination of drugs in several phases, each designed to achieve and maintain cancer remission while minimizing the risk of relapse.

What does chemotherapy for acute lymphocytic leukemia involve?

Chemotherapy for ALL is typically delivered in three phases: induction, consolidation (intensification) and maintenance. Induction therapy aims to eliminate as many leukemic cells as possible to achieve remission. Induction is followed by consolidation therapy to target any remaining cancer cells and help reduce the risk of relapse. Maintenance therapy is a longer, lower-intensity treatment phase designed to keep the cancer in remission. Throughout all phases of ALL treatment, the patient may also receive intrathecal chemotherapy to help prevent or treat the spread of leukemia to the brain and spinal cord.

What are the potential benefits of chemotherapy for acute lymphocytic leukemia?

For many patients with ALL, chemotherapy offers the potential to reach complete remission, especially when the cancer is diagnosed and treated early. In some cases, chemotherapy alone may be sufficient to achieve a cure. In others, it can serve as a bridge to additional therapy, such as bone marrow transplantation. Ongoing advances in chemotherapy drugs and drug regimens continue to improve outcomes and quality of life for both children and adults with ALL.

What are the possible side effects of chemotherapy for acute lymphocytic leukemia?

Chemotherapy targets all rapidly dividing cells. In addition to cancer cells, it may affect healthy cells in the bone marrow, digestive tract and hair follicles, which naturally reproduce at a high rate. If healthy cells are damaged by chemotherapy, side effects may occur, such as:

• Easy bleeding and bruising
• Fatigue and weakness
• Hair thinning and hair loss
• Increased risk of infection
• Mouth sores
• Nausea and vomiting

Some chemotherapy drugs can also affect the heart, liver or nervous system. The specific side effects can vary depending on the medications used, the intensity of treatment and the patient’s overall health.

What is the recovery process like?

Recovery from chemotherapy for ALL can vary widely based on the patient’s age, overall health and response to treatment. During and after chemotherapy, many patients require close monitoring and supportive care, including periodic blood testing, infection prevention measures and nutritional support. Most patients experience periods of fatigue and lowered immunity, particularly during the initial, more intensive phases of treatment. Once chemotherapy is completed and remission is achieved, ongoing follow-up care will be essential to detect any signs of relapse early and monitor for late-onset side effects.

Targeted therapy for acute lymphocytic leukemia

Targeted therapy is an important treatment option for certain forms of ALL, particularly those driven by specific genetic changes. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapy aims to selectively interfere with the molecular processes essential for leukemic cell growth and survival. This precision-based approach allows for more individualized care and may lead to a better outcome with fewer side effects for some patients. Targeted therapy is often used alongside other treatments, such as chemotherapy or bone marrow transplantation, depending on the patient’s age, ALL subtype and overall health.

What does targeted therapy for acute lymphocytic leukemia involve?

Targeted therapy uses specialized drugs or other substances to identify and attack specific molecules involved in the proliferation of leukemic cells. This treatment approach may be considered for ALL if certain genetic mutations or markers are identified, such as the Philadelphia chromosome (Ph+ ALL), which produces an abnormal protein that promotes leukemic cell reproduction. Medications such as tyrosine kinase inhibitors (TKIs)—including imatinib, dasatinib and ponatinib—can block this protein. Other targeted drugs, such as monoclonal antibodies, may be used to bind to specific markers on leukemic cells and either destroy the cells directly or trigger an immune response against them. Targeted therapy may be used alone or in combination with chemotherapy.

What are the potential benefits of targeted therapy for acute lymphocytic leukemia?

Targeted therapy is a highly precise treatment approach that focuses on the unique biological features of cancer cells. In addition to enhancing the overall effectiveness of ALL treatment, its precision can minimize any damage to healthy cells. For patients with Philadelphia chromosome-positive ALL or other targetable abnormalities, targeted therapy can significantly improve remission rates and overall outcomes. In some cases, it may also be used to treat relapsed or refractory ALL, offering an additional option for certain patients who do not respond to standard chemotherapy.

What are the possible side effects of targeted therapy for acute lymphocytic leukemia?

While targeted therapy is generally better tolerated than traditional chemotherapy, it is not without risks. Common side effects include:

• Diarrhea
• Fatigue
• Fever
• Nausea
• Skin rashes

The specific side effects of targeted therapy for acute lymphocytic leukemia can vary depending on the medication used and the patient’s overall health and response to treatment. Some targeted drugs, such as tyrosine kinase inhibitors, may affect liver function, cause fluid retention or impact heart health. Monoclonal antibodies can trigger infusion-related reactions, such as chills, low blood pressure and breathing difficulties. With regular monitoring, the healthcare team can identify and manage any side effects promptly.

Rated High Performing in Leukemia, Lymphoma & Myeloma

Recognized in U.S. News & World Report's Best Hospitals for significantly better performance in leukemia, lymphoma and myeloma treatment than the national average.

Schedule an Appointment

What is the recovery process like?

The recovery process after targeted therapy can vary based on the type of drug used, the duration of treatment and whether it is combined with other therapies. In many cases, targeted therapy can be administered on an outpatient basis, which may support a more stable routine during treatment. As the patient responds to therapy and the leukemia burden decreases, symptoms such as fatigue and infection risk may improve. Ongoing follow-up will be essential to monitor blood counts, assess organ function and detect any signs of recurrence or long-term side effects. While the recovery timeline can vary among patients, many individuals can resume their normal activities during or shortly after treatment.

Immunotherapy for acute lymphocytic leukemia

Immunotherapy is an advanced ALL treatment that harnesses the power of the body’s own immune system to recognize and destroy leukemic cells. It works by targeting specific proteins on the leukemic cells or bolstering the natural ability of the immune system to fight cancer. This treatment approach may be used if standard therapies prove ineffective or if the cancer returns after initial treatment. Immunotherapy is often used in combination with other therapies, such as chemotherapy or bone marrow transplantation, depending on the specific cancer characteristics.

What does immunotherapy for acute lymphocytic leukemia involve?

Several types of immunotherapy may be used to treat ALL. One common approach is monoclonal antibody therapy, which uses lab-made antibodies that target specific proteins on leukemic cells. For example, blinatumomab is a bispecific T-cell engager (BiTE) antibody that connects T cells to cancer cells and helps destroy them. Another option may be CAR T-cell therapy, in which the patient’s own T cells are collected, modified in a lab to better recognize leukemic cells and then infused back into the patient’s body. Immunotherapy is typically administered in a hospital or specialized treatment center and requires close monitoring.

What are the potential benefits of immunotherapy for acute lymphocytic leukemia?

Immunotherapy is a targeted treatment approach that can lead to remission in a patient with relapsed or refractory ALL and may improve the overall outcome. Because immunotherapy is highly specific to cancer cells, it may cause fewer side effects than traditional chemotherapy. Additionally, it can be a valuable treatment option for a patient who is not a candidate for intensive chemotherapy or bone marrow transplantation.

What are the possible side effects of immunotherapy for acute lymphocytic leukemia?

Although immunotherapy is generally well tolerated, it carries certain risks, some of which can be serious. Common side effects include:

• Fatigue
• Fever
• Low blood cell counts
• Nausea

CAR T-cell therapy, in particular, may lead to cytokine release syndrome (CRS), a potentially severe immune reaction that can cause fever, low blood pressure and difficulty breathing. Neurologic effects, such as confusion or seizures, can also occur. These side effects are usually temporary and can often be managed with supportive care and medications, such as corticosteroids.

What is the recovery process like?

Recovery after immunotherapy depends on the type of treatment and the patient’s overall health. Some patients, particularly those receiving CAR T-cell therapy, may be hospitalized for close monitoring in the early stages of treatment. Others may undergo treatment in an outpatient setting but still require frequent follow-up visits to assess blood cell counts, organ function and treatment response. Over time, many patients experience symptom improvement and better blood cell counts, although ongoing monitoring will remain important to detect late-onset side effects or signs of relapse.

Bone marrow transplantation for acute lymphocytic leukemia

Bone marrow transplantation may be a treatment option for certain individuals with ALL, particularly those with high-risk leukemia features and those who experience relapse after initial treatment. The goal of a bone marrow transplant is to replace the patient’s diseased or damaged bone marrow with healthy blood-forming cells, which may be derived from the patient (autologous transplant) or a compatible donor (allogeneic transplant). This treatment approach may be considered after achieving remission with chemotherapy or other treatments.

What does bone marrow transplantation for acute lymphocytic leukemia involve?

The transplant process begins with a conditioning regimen, which typically involves high-dose chemotherapy and possibly radiation therapy. This step is intended to destroy any remaining cancer cells and suppress the patient’s immune system to reduce the risk of rejecting the donor cells. After conditioning therapy is complete, healthy blood-forming cells will be infused into the patient’s bloodstream. Once there, the cells should migrate to the bone marrow, where they may begin producing new, healthy blood cells. The entire process requires careful coordination and is usually performed in a specialized transplant center.

What are the potential benefits of bone marrow transplantation for acute lymphocytic leukemia?

Bone marrow transplantation can offer a potential cure for some individuals with ALL, particularly those with relapsed or refractory leukemia. By replacing the diseased bone marrow with healthy blood-forming cells, the procedure can restore normal blood cell production and help prevent further cancer recurrence. An allogeneic transplant may also provide a “graft-versus-leukemia” effect, in which immune cells from the donor recognize and attack any residual leukemic cells in the patient’s body. This added immune response may improve the long-term outcome.

What are the possible side effects of bone marrow transplantation for acute lymphocytic leukemia?

Bone marrow transplantation carries significant risks and potential complications. Common short-term side effects include:

• Fatigue
• Infections
• Low blood cell counts
• Mouth sores
• Nausea

One of the most serious complications of an allogeneic transplant is graft-versus-host disease (GVHD), a condition in which the donor immune cells attack healthy tissues in the recipient’s body. GVHD can affect the skin, liver, gastrointestinal tract and other organs. Long-term side effects may include hormonal imbalances, infertility and increased risk of secondary cancers. In light of these risks, bone marrow transplantation is typically reserved for patients with a high likelihood of cancer recurrence or progression.

What is the recovery process like?

Recovery from a bone marrow transplant is gradual and may take several months or longer. Most patients remain in the hospital for several weeks after the procedure to be monitored for complications and ensure the transplanted cells begin to function properly. After discharge, frequent follow-up visits will be necessary to monitor blood counts and check for signs of infection, GVHD and relapse. The patient may need to take immunosuppressive medications for some time to help prevent rejection of the donor cells. Full immune system recovery can take a year or longer, and the patient may be advised to avoid certain exposures during this time to help reduce the risk of infection.

Benefit from world-class care at Moffitt Cancer Center

If you would like to learn more about acute lymphocytic leukemia treatment, you can request an appointment with a specialist in the nationally recognized Malignant Hematology Program at Moffitt by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.